REPL
Replimune GroupDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
A recovery case depends on Replimune producing a credible FDA path for RP1 after the second CRL. The packet still shows a $13.00 median target, but analyst count and post-CRL revision detail are unavailable, so that target should not be treated as fresh confirmation.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.1.
What can break
Low-coverage small-cap biotech with no fresh analyst revisions in the packet; valuation anchors may be stale after the regulatory setback.
Momentum
99
Value
41
Sentiment
1
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.00 · Bull $13.00 · Bear $2.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-23 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $10.67
Why
Momentum99 · Δ7d -1.1
Value41 · Δ7d -0.1
Sentiment1 · Δ7d +1.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
99
26% active weight
Current posture
7d trendFlat
Δ7d
-1.1
Δ21d
-1.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
1
34% active weight
Current posture
7d trendImproving
Δ7d
+1.2
Δ21d
+1.2
Why this grade
Composite grade D. Momentum 98.7 / Value 41.1 / Sentiment 1.2
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$858.96M
Beta
0.74
Shares Out
83.96M
P/E (TTM) · Derived
-3.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.20
Rev YoY
-
EPS YoY
-3.2%
Gross Margin
-
Op Margin
-
Net Debt
-$407.64M
Current Ratio
5.60
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology